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ABSTRACT
Primary malignant peritoneal mesothelioma with clear
cell subtype is a rare malignancy with few previously
reported cases. We present a 63-year-old female who
presented with abdominal distention and was diagnosed
with clear cell mesothelioma of the peritoneum with an
isolated metastasis to the liver. The patient underwent
surgical resection of a greater than 50 cm mass with
en-bloc partial liver and gastric resection with an
uneventful post-operative course. There are established
prognostic and treatment recommendations for
peritoneal mesothelioma based on histological subtype
and patient-specific factors, although they do not explicitly
incorporate clear cell subtype. This case report describes
the presentation, treatment and early outcome of a rare
form of peritoneal mesothelioma.

mesothelioma. On immunohistochemical staining, the
tumor was positive for AE1/AE3 and CK7 suggesting an
epithelial neoplasm and positive for calretinin, CK/CK6,
and WT-1. It was negative for colorectal, GIST, hepatocellular, mullerian and renal tumor markers. The
pathology was reviewed at two centers with concordant
impressions. Given the histology, the patient was
scheduled for a laparotomy and resection of her
abdominal mass.

A

INTRODUCTION
Primary malignant peritoneal mesothelioma is a rare
malignancy. Clear cell subtype of the epithelioid variant
is even rarer, with very few cases reported in the
literature.1-3 In this case we present a 63 year-old female
who presented with abdominal distention, who was
fo un d to have p rim a r y m a li gna nt p e rito n ea l
mesothelioma of clear cell subtype with hepatic
metastases who ultimately underwent surgical resection
with plan for adjuvant chemotherapy. Due to the lack of
a well-defined presentation pattern or therapeutic
strategy for this specific subtype, it is important to report
this case and its outcomes.

B

CLINICAL SUMMARY
The patient is a 63 year-old female who presented with a
6-month history of gradually increasing abdominal girth,
discomfort, and early satiety. She underwent esophagogastroduodenoscopy and colonoscopy, which were
found to be normal. On abdominal computed
tomography she was found to have an intra-abdominal
mass 26 cm in size that appeared to be arising from the
epigastrium and a 5cm centrally located hepatic mass
consistent with solitary hepatic metastasis (Figure 1). The
abdominal mass appeared to be encapsulated and there
was no evidence of diffuse disease in the peritoneal
cavity. The patient underwent a percutaneous biopsy of
the mass with histopathology diagnosing as clear cell

Figure 1. Axial (a) and coronal (b) abdominal computed tomography
illustrating an intra-abdominal mass approximately 26cm in size that
appeared to be arising from the epigastrium and a 5cm centrally located
hepatic mass consistent with solitary hepatic metastasis.
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DISCUSSION

Figure 2. Intra-operatively the mass was greater than 50 cm in diameter.
The mass was adherent to and infiltrating the capsule of the left lateral
segment of the liver and adherent to but not infiltrating the transverse colon.

On admission, she was noted to have leukocytosis to
16,100/μl and found to have a urinary tract infection,
which was treated with a regimen of levofloxacin. She
was anemic with a hemoglobin of 7.3g/dl, a platelet
count of 830,000/ μl, a prothrombin time of 18.7
seconds, an albumin of 3.1g/dl, and prealbumin of
7.2mg/dl. On hospital day two, the patient underwent
surgical resection. During the procedure, the mass was
found to be greater than 50 cm in diameter, filling the
entire abdomen and appeared to be arising from the
greater omentum and distal stomach. The mass was
densely adherent to and infiltrating the capsule of the
left lateral segment of the liver and adherent to but not
infiltrating the transverse colon (Figure 2). A distal
gastrectomy and partial hepatectomy were performed
en bloc with the mass and a Roux-en-Y gastrojejunostomy was performed. The liver lesion was left in situ
given its central location and there was no evidence of
any other peritoneal dissemination.
The patient required one unit of packed red blood cells
with an adequate response and otherwise had an
uncomplicated post-operative course with normalization
of her leukocytosis. She was discharged on postoperative day seven. Pathology of the resected
specimens confirmed clear cell malignant mesothelioma
with negative surgical margins. Upon recovery, the liver
metastasis will be restaged and treated with systemic or
regional therapy.
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Malignant mesothelioma is a rare malignancy of the
serosal membranes of the pleura, peritoneum,
pericardium, or tunica vaginalis testes. There are only
3300 cases of mesothelioma diagnosed in the United
States every year, with only 10 to 15 percent peritoneal in
etiology.4 Tumors derived from the serosal membranes
often grow in a variety of histologic patterns. According
to their light microscopic appearance, mesotheliomas
have been subdivided into epithelioid, sarcomatoid,
mixed epithelioid and sarcomatoid (biphasic), and
desmoplastic subtypes. The most frequent histologic
type of malignant mesothelioma is epithelioid. While
epithelioid mesotheliomas usually have a tubulopapillary,
adenomatoid, or solid pattern, on rare occasions they
may also present with other histologic patterns including
deciduoid, pleomorphic, small cell, signet-ring, as well as
clear cell which is characterized by cells with cytoplasmic
clearing usually caused by the accumulation of large
amounts of intracytoplasmic glycogen.5,7
Predominately clear cell mesothelioma is an especially
rare finding with fewer than 30 cases reported in the
literature, and even rarer to present specifically in the
peritoneum, with only one previous case reported in the
peritoneum of a female patient.1-3,5-7 While the tumor can
occur in children and young adults, it is usually found in
older adults. Males and females are equally affected,
however males are at a higher risk due to increased
occupational exposure.4 While the etiology of malignant
clear cell mesothelioma is unknown, it has been
associated with asbestos exposure, radiation treatment,
and mutations in the BAP1 gene.8 The symptoms can
often be unspecific and depend on the size and location
of the tumor. Small sized tumors may be asymptomatic
during the initial stages of tumor growth while
large-sized tumors can present with pain, obstructive
symptoms, fatigue, and weight loss. Our patient
presented with relatively mild symptoms that appeared
to be caused by compression rather than infiltrative
effects and she continued to maintain an excellent
performance scale with an ECOG score of 1 despite the
size of the mass in her abdomen.
In order to diagnose clear cell mesothelioma in our
patient, an initial diagnosis was made after a complete
evaluation of the patient’s history and physical along
with an abdominal CT scan. While imaging tools such as
CT, MRI, and PET scan may reveal the presence of a
tumor, a tissue biopsy is necessary to make a definitive
diagnosis. The differential diagnosis for malignant
mesothelioma depends on the predominant histologic
category. Most tumors are a mixture of more than one
cell type; therefore, due to the rarity of clear cell
mesothelioma this diagnosis can often be missed. While
immunohistochemical staining plays an important role

in the workup of malignant mesothelioma, IHC varies
depending on the histological type of mesothelioma,
the location of the tumor, and the type of tumor being
considered in the differential diagnosis. These variants
can often be confused with a variety of other neoplastic
conditions with a similar clear cell morphology.8 In our
case this patient’s diagnosis was confirmed by immunohistochemical studies which demonstrated reactivity for
calretinin, keratin 5/6, and WT1, an important pattern
that is characteristic of mesothelioma. Calretinin is
demonstrated in nearly all epithelioid mesotheliomas,
keratin 5/6 is expressed in 75%–100% of mesotheliomas,
and approximately 70%–95% of mesotheliomas show
nuclear positivity for WTI. In addition, we were careful to
rule out other causes of clear cell tumors. The diagnosis
of epithelioid mesothelioma with clear cell morphology
can often be difficult as it must be differentiated from
clear cell renal cell carcinomas, clear cell carcinomas of
the lung, clear cell melanoma, and other clear cell
tumors that can metastasize to the pleura or peritoneum.
Therefore, immunohistochemical panels should contain
both positive and negative markers for mesothelial
differentiation and for neoplasms considered in the
differential diagnosis.9
Clear cell mesothelioma is a highly aggressive cancer
that requires a multidisciplinary approach. The prognosis
for malignant peritoneal mesothelioma is relatively poor
due to organ dysfunction, local invasion and metastasis,
and the high rate of recurrence. Stage and histology are
the strongest prognostic factors among patients with
mesothelioma, with sarcomatoid and biphasic histologic
subtypes having worse outcomes compared with
epithelioid mesothelioma. In addition to size, stage, and
grade of the tumor, prognosis generally depends on a
combination of factors including age, overall health of
the patient, cell growth rate, and response to treatment.10
The European Organization for Research and Treatment
of Cancer (EORTC) has developed prognostic scoring
systems for peritoneal mesothelioma. They reviewed
data from 204 adults with malignant peritoneal
mesothelioma and when five factors were taken into
consideration (poor performance status, high white
blood cell count, male gender, sarcomatous subtype,
and the certainty of the diagnosis), a low risk group with
a prognostic score of 0-2 poor prognostic factors and a
high risk group with >3 prognostic factors were found to
have a one-year survival rates of 40 and 12 percent,
respectively.11 Median survival from the date of study
entry was 8.4 months. Similarly, the Cancer and Leukemia
Group B (CALGB) evaluated 337 patients with malignant
mesothelioma and found that pleural involvement,
increased serum LDH, poor performance status, chest
pain, increased platelet count, non-epithelial histology,
and age older than 75 years predicted poor survival.

These factors were differentiated into six prognostic
subgroups with median survival times ranging from 1.4 to
13.9 months with a median survival overall of seven
months.11 Using these scoring systems our patient fell
into the low risk subgroup with a 40% survival rate of one
year and a mean survival rate of 9 months. Though our
patient was older with a high-grade, bulky tumor, due to
her previous good health and the resectability of her
tumor given the encapsulated nature of the tumor, we
determined that she was a good candidate for surgery.
We hope that this case demonstrates the importance of
recognizing clear cell variant mesothelioma early and
understanding predictive prognosis given individual
patient characteristics. Through early detection, we can
avoid complications and help increase positive outcomes.
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